MEI Pharma and Kyowa Kirin Announce Global License, Development and Commercialization Agreement for ME-401
MEI Pharma, Inc. (MEIP)
Last mei pharma, inc. earnings: 2/6 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.meipharma.com
Company Research
Source: Business Wire
MEI Pharma and Kyowa Kirin will co-develop and co-promote ME-401 in the U.S.; MEI to book U.S. sales on 50-50 profit and cost sharingKyowa Kirin obtains exclusive commercialization rights ex-U.S.; MEI to receive escalating tiered royalty payments on ex-U.S. sales MEI to receive $100 million in an upfront cash payment and is eligible to receive up to an additional $582.5 million based on the achievement of specified development, regulatory and commercial milestonesMEI to host conference call on April 14 at 8:00 a.m. ET SAN DIEGO & TOKYO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP) and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TOKYO: 4151) today jointly announced that the companies have entered into a global license, development and commercialization agreement to further develop and commercialize MEI’s ME-401, an oral, once-daily, investigational drug-candidate, selective for phosphatidylinositol 3-kinase delta (PI3Kd), in clinical development for the treatment of B-cell malignancies
Show less
Read more
Impact Snapshot
Event Time:
MEIP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MEIP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MEIP alerts
High impacting MEI Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
MEIP
News
- MEI Pharma, Inc. (NASDAQ: MEIP) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.MarketBeat
- MEI Pharma GAAP EPS of -$1.20 [Seeking Alpha]Seeking Alpha
- MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position [Yahoo! Finance]Yahoo! Finance
- MEI Pharma Reports First Quarter Fiscal Year 2025 Cash PositionBusiness Wire
- MEI Pharma, Inc. (NASDAQ: MEIP) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.MarketBeat
MEIP
Earnings
- 5/9/24 - Beat
MEIP
Sec Filings
- 11/14/24 - Form 8-K
- 11/12/24 - Form 10-Q
- 10/25/24 - Form 8-K
- MEIP's page on the SEC website